However, although modest therapeutic effects of TZD on steatosis of patients with NASH have been consistently reported, there is not a consensus in the effects that pharmacological activation of PPARγ may have on fibrosis in patients with NASH. Here, PPARG is linked to metabolic dysfunction-associated steatohepatitis.